Alpha Cognition Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Alpha Cognition Inc. (Nasdaq: ACOG), a British Columbia corporation, on April 7, 2025. The report discloses changes to the Board of Directors, specifically the departure of a director and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Base Salary (Dr. Wills): $40,000
- Committee Retainer (Dr. Wills): $5,000 annually
- Stock Option Grant (Dr. Wills): 35,575 options at an exercise price of $4.83 per share
Material Changes
The primary material change reported is the composition of the Board of Directors:
- Departure: John Havens informed the Company on April 7, 2025, of his intention not to run for re-election at the 2025 annual meeting. The filing states this decision was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Robert Wills, Ph.D., was appointed to the Board and the Governance and Nominating Committee, effective April 7, 2025.
Outlook, Risks, and Management Commentary
Management Commentary: The Company highlighted Dr. Wills' extensive background, including over four decades of experience in the pharmaceutical and biotechnology industries. His prior roles include leadership positions at Johnson & Johnson, GTx, Inc., and CymaBay Therapeutics, as well as current board service at Milestone Pharmaceuticals, Parion Sciences, and Oncternal Therapeutics.
Compensation Structure: Dr. Wills' stock options vest over 24 months, with 12.5% vesting on the grant date and the remainder vesting quarterly thereafter. The filing confirms no family relationships or undisclosed material interests between Dr. Wills and other directors or officers.
Risks and Contingencies: No specific risks or contingencies were disclosed in this filing.
Key Facts for Investor Verification
- Verify the exact date of John Havens' departure from the Board relative to the 2025 annual meeting schedule.
- Confirm the vesting schedule and exercise price ($4.83) of the 35,575 stock options granted to Dr. Wills under the 2023 Stock Option Plan.
- Review the updated Board composition to assess the impact of Dr. Wills' pharmaceutical industry expertise on the Company's strategic direction.
- Note that this filing contains no financial results; investors should refer to the most recent 10-K or 10-Q for financial performance data.